Treatment of the chronic itch of atopic dermatitis using standard drugs and Kampo medicines

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 8, 2013, Pages 1253-1257

  Yamashita, Hirotaka ^a   Tanaka, Hiroyuki ^a   Inagaki, Naoki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atopic dermatitis; Chronic itching; Kampo medicine; Murine model; Pharmacotherapy

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; BU ZHONG YI QI TANG; CORTICOSTEROID; DERMATOLOGICAL AGENT; DEXAMETHASONE; FEXOFENADINE; GLUCOCORTICOID RECEPTOR ALPHA; HISTAMINE H1 RECEPTOR; HYDROCORTISONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; JUZENTAIHOTO; KAMPO; LEUKOTRIENE; MOISTURIZING AGENT; ORENGEDOKUTO; PLACEBO; PROSTAGLANDIN; SHOFUSAN; SUBSTANCE P; TACROLIMUS; UNCLASSIFIED DRUG; YOKUKANSAN;

ALLERGY; ARTICLE; ATOPIC DERMATITIS; CHINESE MEDICINE; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CHRONIC URTICARIA; CUTANEOUS PARAMETERS; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; ECZEMA; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MAST CELL DEGRANULATION; MOISTURE; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PROTEIN DEPLETION; PROTEIN INDUCTION; PRURITUS; RECURRENT DISEASE; SCRATCHING; SKIN BURNING SENSATION; SKIN INFECTION; SKIN MOISTURE; SKIN PRURITUS; TH1 TH2 BALANCE; TREATMENT INDICATION;

EID: 84883181255     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00332     Document Type: Article

References (40)

1. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, Sasaki R, Suto H, Takehara K, Committee for Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association. Guidelines for management of atopic dermatitis. J. Dermatol., 36, 563-577 (2009).
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet., 38, 441-446 (2006).
3. Marenholz I, Nickel R, Rüschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, Grüber C, Lau S, Worm M, Keil T, Kurek M, Zaluga E, Wahn U, Lee YA. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J. Allergy Clin. Immunol., 118, 866-871 (2006).
4. Kamata Y, Taniguchi A, Yamamoto M, Nomura J, Ishihara K, Takahara H, Hibino T, Takeda A. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J. Biol. Chem., 284, 12829-12836 (2009).
5. Wahlgren CF. Itch and atopic dermatitis: an overview. J. Dermatol., 26, 770-779 (1999).
6. Kobayashi H, Takahashi K, Mizuno N, Kutsuna H, Ishii M. An alternative approach to atopic dermatitis: Part I-Case-series presentation. Evid. Based Complement. Alternat. Med., 1, 49-62 (2004).
7. Kobayashi H, Takahashi K, Mizuno N, Kutsuna H, Ishii M. An alternative approach to atopic dermatitis: Part II-Summary of cases and discussion. Evid. Based Complement. Alternat. Med., 1, 145-155 (2004).
8. Katayama I, Kohno Y, Akiyama K, Ikezawa Z, Kondo N, Tamaki K, Kouro O; Japanese Society of Allergology. Japanese guideline for atopic dermatitis. Allergol. Int., 60, 205-220 (2011).
9. Kijima A, Murota H, Takahashi A, Arase N, Yang L, Nishioka M, Yamaoka T, Kitaba S, Yamauchi-Takihara K, Katayama I. Prevalence and impact of past history of food allergy in atopic dermatitis. Allergol. Int., 62, 105-112 (2013).
10. Lodén M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br. J. Dermatol., 140, 264-267 (1999).
11. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids, 75, 1-12 (2010).
12. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell, 62, 1189-1204 (1990).
13. Maneechotesuwan K, Yao X, Ito K, Jazrawi E, Usmani OS, Adcock IM, Barnes PJ. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med., 6, e1000076 (2009).
14. Akabane H, Murata M, Kubota M, Takashima E, Tanaka H, Inagaki N, Horiba M, Nagai H. Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells. Allergol. Int., 55, 387-393 (2006).
15. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin. Ther., 19, 710-719 (1997).
16. Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB Jr. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm. Venereol., 92, 455-461 (2012).
17. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, Koga T. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br. J. Dermatol., 148, 128-133 (2003).
18. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl. Acad. Sci. U.S.A., 89, 3686-3690 (1992).
19. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taïeb A, Gratton D, Sauder D, Sharpe G, Smith C, Jünger M, de Prost Y, European/Canadian Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J. Allergy Clin. Immunol., 109, 539-546 (2002).
20. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schoepf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T, European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol., 109, 547-555 (2002).
21. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M, The European Tacrolimus Ointment Study Group. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch. Dermatol., 136, 999-1006 (2000).
22. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N. Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur. J. Pharmacol., 645, 171-176 (2010).
23. Inagaki N, Shiraishi N, Igeta K, Itoh T, Chikumoto T, Nagao M, Kim JF, Nagai H. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. Eur. J. Pharmacol., 546, 189-196 (2006).
24. Inagaki N, Shiraishi N, Igeta K, Nagao M, Kim JF, Chikumoto T, Itoh T, Katoh H, Tanaka H, Nagai H. Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur. J. Pharmacol., 626, 283-289 (2010).
25. Yamashita H, Makino T, Mizukami H, Nose M. Pharmacological characterization of a chronic pruritus model induced by multiple application of 2,4,6-trinitrochlorobenzene in NC mice. Eur. J. Pharmacol., 563, 233-239 (2007).
26. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol., 135, 1522-1525 (1999).
27. Shichijo M, Inagaki N, Nakai N, Kimata M, Nakahata T, Serizawa I, Iikura Y, Saito H, Nagai H. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin. Exp. Allergy, 28, 1228-1236 (1998).
28. Kamei H, Isaji A, Noda Y, Ishikawa K, Senzaki K, Yamada K, Sugiura K, Tomita Y, Nabeshima T. Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers. Arch. Dermatol. Res., 304, 263-272 (2012).
29. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br. J. Dermatol., 148, 1212-1221 (2003).
30. Kamiyama H, Takano S, Ishikawa E, Tsuboi K, Matsumura A. Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma. Biol. Pharm. Bull., 28, 2111-2116 (2005).
31. Kiyohara H, Nonaka K, Sekiya M, Matsumoto T, Nagai T, Tabuchi Y, Yamada H. Polysaccharide-containing macromolecules in a Kampo (traditional Japanese herbal) medicine, hochuekkito: Dual active ingredients for modulation of immune functions on intestinal Peyer's patches and epithelial cells. Evid. Based Complement. Alternat. Med., 2011, 1-B (2011).
32. Kiyohara H, Nagai T, Munakata K, Nonaka K, Hanawa T, Kim SJ, Yamada H. Stimulating effect of Japanese herbal (Kampo) medicine, hochuekkito on upper respiratory mucosal immune system. Evid. Based Complement. Alternat. Med., 3, 459-467 (2006).
33. Gao XK, Fuseda K, Shibata T, Tanaka H, Inagaki N, Nagai H. Kampo medicines for mite antigen-induced allergic dermatitis in NC/Nga mice. Evid. Based Complement. Alternat. Med., 2, 191-199 (2005).
34. Kobayashi H, Ishii M, Takeuchi S, Tanaka Y, Shintani T, Yamatodani A, Kusunoki T, Furue M. Efficacy and safety of a traditional herbal medicine, hochu-ekki-to in the long-term management of kikyo (delicate constitution) patients with atopic dermatitis: A 6-month, multicenter, double-blind, randomized, placebo-controlled study. Evid. Based Complement. Alternat. Med., 7, 367-373 (2010).
35. Kato S, Kato TA, Nishie H, Nishima S, Iwanaga T, Monji A, Nakano M, Takeshita H, Furue M. Successful treatment of chronic urticaria with a Japanese herbal medicine, yokukansan. J. Dermatol., 37, 1066-1067 (2010).
36. Jiang J, Yamaguchi T, Funakushi N, Kuhara T, Fan PS, Ueki R, Suto H, Kase Y, Ikeda S, Ogawa H. Oral administration of Yokukansan inhibits the development of atopic dermatitis-like lesions in isolated NC/Nga mice. J. Dermatol. Sci., 56, 37-42 (2009).
37. Funakushi N, Yamaguchi T, Jiang J, Imamura S, Kuhara T, Suto H, Ueki R, Kase Y, Kobayashi H, Ogawa H, Ikeda S. Ameliorating effect of Yokukansan on the development of atopic dermatitis-like lesions and scratching behavior in socially isolated NC/Nga mice. Arch. Dermatol. Res., 303, 659-667 (2011).
38. Yamashita H, Tasaki D, Makino T, Matsuoka K, Nose M, Inagaki N, Mizukami H. The role of IgE and repeated challenge in the induction of persistent increases in scratching behavior in a mouse model of allergic dermatitis. Eur. J. Pharmacol., 605, 153-157 (2009).
39. Yamashita H, Michibata Y, Mizukami H, Ogihara Y, Morita A, Nose M. Dermal mast cells play a central role in the incidence of scratching behavior in mice induced by multiple application of the hapten, 2,4,6-trinitrochlorobenzene. Exp. Dermatol., 14, 438-444 (2005).
40. Yamashita H. Assessment of relief from pruritus due to Kampo medicines by using murine models of atopic dermatitis. J. Trad. Med., 30, in press (2013).